Physician profile
Himja Bhatt
NPI 1285282210
$4,081.94
in general payments reported to CMS, 2019-2025
24 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $264 · 2022: $286 · 2023: $430 · 2024: $1,209 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.07 |
| Education | $310.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $699.33 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $677.87 | 2021-2025 | Odomzo, Ilumya, Blu-U |
| Lilly USA, LLC | $292.18 | 2023 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $289.73 | 2024-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $276.31 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $253.55 | 2022-2025 | Libtayo |
| Arcutis Biotherapeutics, INC. | $173.96 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $169.19 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Organon LLC | $168.83 | 2024-2025 | Vtama |
| Ucb, INC. | $152.76 | 2024-2025 | Bimzelx |
| Organogenesis INC. | $140.17 | 2024-2025 | Puraply Wound Matrix |
| Novartis Pharmaceuticals Corporation | $131.89 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $112.59 | 2025 | Cabtreo |
| Inspire Medical Systems, INC. | $107.01 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $77.65 | 2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $55.69 | 2024-2025 | Sotyktu |
| Biofrontera INC. | $51.40 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $45.81 | 2023 | |
| Kerecis Limited | $30.13 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Amgen INC. | $28.44 | 2025 | Otezla |
| Dermavant Sciences, INC. | $19.88 | 2024 | Vtama |
| Journey Medical Corporation | $14.76 | 2025 | |
| Janssen Pharmaceuticals, INC | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himja Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.